HAI-ROBOTICS
24.3.2022 13:59:10 CET | Business Wire | Press release
HAI ROBOTICS will display its Autonomous Case-handling Robot (ACR) systems in Europe at the upcoming Transport and Logistics Innovation Week (SITL) 2022 in Paris from Apr. 5-8, an event it sees as the launchpad into more European countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005462/en/
SITL 2022 will also mark the debut of the company's local European team.
Considered a disruptive innovator, HAI ROBOTICS is committed to spearheading the future of warehouse automation, with a flexible, easily deployable and cost-effective solution that will massively increase supply chain efficiency in Europe.
Local Presence
Since setting up its regional headquarters in the Netherlands in late 2021, HAI ROBOTICS has expanded its presence quickly into several countries, such as France, Germany, Spain, Italy, the Benelux and the U.K.
It has quickly set up a local team, most of whom are industrial veterans.
Peter Guan, HAI ROBOTICS European General Manager, said HAI Robotics "is dedicated to hiring local top talent in each of the European key regions."
"The company has already employed the services of several native country managers with proven track records in the logistics automation industry. We keep searching for more local talent that can increase the level of our service and support," Mr Guan said.
"We are gearing up to do more exhibitions in Europe," he added.
An expert in building up, structuring and swiftly growing the European business of international companies that want to break into the market, Mr Guan used to be the sales & marketing director at Hikvision for more than ten years.
At SITL 2022, Mr Guan will be joined by Kai Ramadhin, VP of Sales & Marketing Europe, and Thierry Hennebiq, Country Manager France. Both were newly joined.
With more than 20 years of experience in the logistics market, Mr Ramadhin had previously worked with the Dutch corporation Van Riet Material Handling Systems as both interim CEO and the Director of Sales and Marketing.
With more than 10 years of experience in the intralogistics industry, Mr Hennebiq had previously fulfilled roles at the top system integrators in this industry including TGW, Dematic and Vanderlande.
The Better Fit
Compared with existing, especially traditional, warehouse automation solutions, HAI ROBOTICS believe its ACR systems are a better fit for European customers.
Take France, where SITL 2022 convenes, for example. Mr Hennebiq said "huge demand is observed," given the growing demand for logistic services.
"We think our ACR solution can give logistic service suppliers everything they need to optimize their warehouses for massively increased throughput and efficiency," he said.
Mr Ramadhin said HAI ROBOTICS' target industries include mainly 3PL, retail & e-commerce, fashion and FMCG. "Our ACR solution is catered to handle products in these markets."
Compared to logistic service suppliers employing a traditional human labor force, Mr Ramadhin said the ACR systems can "exponentially increase operational efficiency," whilst requiring less time to implement and being more cost-effective than traditional automation solutions.
"HAI ROBOTICS solution provides more flexibility in term of expansion ability, rapid deployment times and so on. So the sweet-spot of our solution is much more attractive," he said.
Mr Ramadhin noted the company is focused on creating a local network of system integrator, installation and service partners, so that any user of ACR systems can expect rapid and high-quality service wherever they are in Europe.
Since its foray into Europe last year, HAI ROBOTICS' presence has been expanding swiftly in the local warehousing logistics sector.
It has paired up with France-based global logistics solutions engineering company Savoye and has inked a strategic partnership with Greece's market leader in intralogistics Voyatzoglou Systems.
At a time when e-commerce booms, the company's ACR solution was deployed at a Micro-Fulfillment Center in Europe, significantly improving the last-mile delivery.
"We aim to provide our customers with high quality service and support, both through our own regional teams, as well as our robust network of installation and service partners," Mr Ramadhin said.
To see HAI ROBOTICS's ACR systems live, please visit booth K81, Paris - Nord Villepinte - Hall 6, during SITL 2022.
ABOUT HAI ROBOTICS
HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005462/en/
Link:
Social Media:
https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
